Dr Reddy’s has launched the injection at an affordable price, making it readily available for patients. The company’s capacity to adequately supply Dexmedetomidine is significant as it's on the FDA’s drug shortage list.

Granules India Limited today announced that United States Food & Drug Administration (USFDA) has approved its abbreviated new drug application (ANDA) for Naproxen Sodium and Diphenhydramine Hydrochloride tablets, 220 mg/25 mg (OTC), which is a generic equivalent of Aleve PM Tablets, 220 mg/25 mg, of Bayer HealthCare LLC.

On Friday, the shares of Vakrangee Limited locked in at its upper circuit of 10 per cent at Rs 27.10 per share. The jump in the stock price was due to the company’s announcement about being granted an in-principle authorisation to set-up and operate the Bharat Bill Payment Operating Unit (BBPOU) by Reserve Bank of India (RBI).

Tata Consultancy Services (TCS), a leading global IT services, consulting, and business solutions organization, has partnered with Maurices, a women’s fashion-apparel retail chain in the US and Canada, to help create a new flexible and scalable IT landscape for the latter.

The market opened in green on September 25, 2020, overall volumes in futures & options currently stand at 6,71,01,341 crore contracts with a turnover of Rs. 43,02,566.44 crore.

The market opened in green on September 25, 2020.

The market opened in green on September 25, 2020, overall volumes in futures & options currently stand at 6,71,01,341 crore contracts with a turnover of Rs. 43,02,566.44 crore.

Cipla Limited today announced that it has received final approval for its abbreviated new drug application (ANDA) for Dimethyl Fumarate DR Capsules 120mg, 240mg, and 120mg/240mg starter pack from United States Food & Drug Administration (USFDA).

The onus is on the 200-DMA, which is placed at 10,761. If bulls manage to defend it, expect a pullback up to the levels of 10,980, or else, 10,640-10,550 is the next destination. Stocks in news: Cipla, GMR Infrastructure, ONGC, GAIL, RITES, TCS.

The Indian markets are gripped by three key factors namely, fear, uncertainty, and doubt. The fear is rising as it is quite evident from the surge in India VIX. Uncertainty is hovering over as some countries are planning another lockdown to combat the spread of Coronavirus and doubt over the pace of economic recovery.